| Name | Terlipressin Acetate |
| Description | Terlipressin Acetate, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research. |
| In vitro | Incubation with 25 nM terlipressin significantly improved cell viability, proliferation and apoptosis. Furthermore, terlipressin inhibited the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following OGD/R[1]. |
| In vivo | Using a mouse nonlethal hepatic IR model, we found terlipressin administration significantly ameliorated IR-induced liver apoptosis, necrosis and inflammation[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 245 mg/mL (181.82 mM), Sonication is recommended.
|
| Keywords | VasopressinReceptor | vasopressin V1 | Vasopressin Receptor | vasoconstriction | variceal | V1-receptors | Terlipressin Acetate | Terlipressin | bleeding | anti-oxidative |
| Inhibitors Related | Mozavaptan | Desmopressin acetate (16679-58-6 free base) | OPC-51803 | Felypressin acetate | Nelivaptan | PF-184563 | Ornipressin Acetate(3397-23-7,free) | d[Leu4,Lys8]-VP acetate | E-4177 | Fuscoside | Tolvaptan | WAY-267464 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Cyclic Peptide Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Peptide Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |